Business Context and Reporting Period
This Form 8-K filing by FS KKR Capital Corp. (FSK) reports a corporate governance event dated July 8, 2019. The filing details the appointment of a new independent director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The primary material change is the appointment of Mr. Osagie Imasogie as a new independent Class B Director, effective July 8, 2019. His term expires at the 2021 annual meeting of stockholders. Additionally, Mr. Imasogie will join the Valuation Committee and replace Mr. Goldstein on the Audit Committee.
Management Commentary and Compensation
Mr. Imasogie brings over 30 years of experience in law, finance, and the life sciences sector, including roles as Senior Managing Partner of PIPV Capital and founding positions at GlaxoSmithKline Ventures. He will receive director fees consistent with the Fund Complex arrangements, which include an aggregate annual board retainer of $160,000 paid pro rata based on assets under management. The filing states no agreement or understanding existed regarding his election.
Investor Verification Checklist
- Confirm the effective date of Mr. Imasogie's appointment (July 8, 2019).
- Verify the specific committee assignments: Valuation Committee (new) and Audit Committee (replacing Mr. Goldstein).
- Review the compensation structure regarding the $160,000 aggregate annual retainer shared across the Fund Complex.
- Check for any potential conflicts of interest given Mr. Imasogie's extensive background in private equity and pharmaceuticals.